Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

SAN FRANCISCO, CA—Transcatheter mitral valve replacement (TMVR) with the novel Sapien M3 device (Edwards Lifesciences) is associated with low rates of adverse clinical outcomes and sustained ...

NEWBURY, May 8 2024 -- Edwards Lifesciences today announced the UK launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company’s breakthrough ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

This is for you, PrimalScript fans: My contacts at Sapien allowed me to leak a few teasers about the next version of PrimalScript that will hit the streets around August 1. The new 2007 release of ...